Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-17
2007-07-17
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S334000, C546S256000, C546S257000
Reexamination Certificate
active
10651023
ABSTRACT:
The compounds of the present invention are of formula I:wherein A, R3, R4is as defined herein, are useful as ligands for nicotinic receptors.
REFERENCES:
patent: 5559124 (1996-09-01), Bencherif et al.
patent: 5602257 (1997-02-01), Zoltewicz et al.
patent: 5734059 (1998-03-01), Watanabe et al.
patent: 5741802 (1998-04-01), Kem et al.
patent: 5977144 (1999-11-01), Meyer et al.
patent: 2002/0028798 (2002-03-01), Demopulos et al.
patent: 2361437 (2000-08-01), None
patent: 196 22 353 (1997-12-01), None
patent: WO 92/15306 (1992-09-01), None
patent: WO 94 05288 (1994-03-01), None
patent: WO 98 03484 (1998-01-01), None
patent: WO 99 10338 (1999-03-01), None
patent: WO 01/73446 (2001-10-01), None
patent: WO 03 057140 (2003-07-01), None
W. R. Kem, “The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21)”, Behavioural Brain Research, Elsevier, vol. 113, No. 1/2, 2000, pp. 169-181.
C. De Fiebere, et al., “Characterization of a series of Anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative . . . ”,Molecular Pharm., vol. 47, No. 1, 1995, pp. 164-171.
Jeffrey D. Schmitt et al., “Chapter 5. Targeting Nicotinic Acatylcholine Receptors: Advances in Molecular Design and Therapies”Annual Reports in Medicinal Chemistry—35, pp. 41-51.
Mark W. Holladay et al., “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery”Journal of Medicinal Chemistery, 1997, vol. 40, No. 26, pp. 4169-4194.
Michael W. Decker et al., “Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for CNS Therapeutics”Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for CNS Therapeutics, 2000, pp. 1-14.
Dwight Flammia et al., “Iobeline: Structure-Affinity Investigation of Nicotinic Acetylcholinergic Receptor Binding”J. Med. Chem. 1999, vol. 42, No. 18, pp. 3726-3731.
R. Azuma et al., “Metabolism and Disposition of GTS-21, a novel drug for Alzheimer's disease”Xenobiotica, 1999, vol. 29, No. 7, pp. 747-762.
Karen E. Stevens et al., “Selective α7-nicotinic agonists normalize inhibition of auditory repsonse in DBA mice”Psychipharmacology1998, No. 136, pp. 320-327.
Ryotaro Azuma et al., “The effect of repeat administration of GTS-21 on mixed-function oxidase activities in rat”,Toxicology Letters 110, 1999, pp. 137-144.
Alberici et al., Tet. Lett, 24(18) (1983), pp. 1937-1940.
De Kimpe, et al., Tet. Lett. 34(29) (1993), pp. 4693-4696.
Leete, J. org. Chem., 44(2), (1979), pp. 165-168.
Mundy et al., Synthetic Commun., 2(4), (1972), pp. 197-200.
Sultana et al., Biorganic & Medicinal Chemistry, 10 (2002), pp. 2963-2971.
Villemin et al., React. Kinet. Catal. Lett, 72(1), (2001), pp. 3-10.
Zoltewicz et al., Heterocycles, vol. 35, No. 1 (1993), pp. 171-180.
Zoltewicz et al., J. org. Chem., (1989), 54, pp. 4462-4468.
Zoltewicz et al., OPPI Briefs, 27,4 (1995), pp. 510-513.
Herbert Brian
Hopper Allen T
Nguyen Truc Minh
Tehim Ashok
Xie Wenge
Davis Zinna N.
Memory Pharmaceuticals Corp.
Millen White Zelano & Branigan P.C.
LandOfFree
Heterocyclic compounds, methods for the preparation thereof,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, methods for the preparation thereof,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds, methods for the preparation thereof,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3772564